Phase 1 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older
- People with a type of blood cancer called AML (acute myeloid leukemia) that is unlikely to be cured with currently available treatments
- People whose AML has not gone into full remission (meaning the cancer has not fully responded to treatment), or whose disease has come back after treatment, including cases that never responded to treatment in the first place
- People whose AML has come back after a bone marrow/stem cell transplant — including cases where the cancer has not visibly returned but is still detectable through lab tests (confirm with trial site)
- People who have relapsed after a transplant and have been off immune-suppressing medications for at least one month before enrolling
- People who have a suitable stem cell donor available
- People whose kidneys, liver, and heart are functioning well enough to meet the trial's requirements (the trial site will assess this with specific tests)
- People whose heart is pumping at 40% efficiency or better, confirmed by a heart scan
- People whose lungs are functioning at more than 45% of the expected level
- People who are generally well enough to carry out daily activities with no more than mild limitations (assessed using a standard scale called the ECOG scale, scores 0–1)
- People who are willing to use acceptable birth control methods if there is any chance of pregnancy
Who may not be able to join:
- People who are pregnant or currently breastfeeding
- People with an active hepatitis B, hepatitis C, or HIV infection
- People currently taking systemic (whole-body) steroids or other immune-suppressing medications
- People with any serious uncontrolled medical condition that would make participation unsafe
- People showing signs or symptoms that suggest the cancer may have spread to the brain or spinal cord
- People with a known allergy or sensitivity to any of the substances used in the study product, specifically human serum albumin, DMSO, or Dextran 40
- People with serious heart conditions classified as Class III or IV by standard heart disease guidelines
- People who have had a clinically significant irregular heartbeat, or an irregular heartbeat that is not well-controlled with medication, within two weeks of the screening visit
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Noelle Frey, MD, University of Pennsylvania
Phone: 215-349-8245
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Manufacturing feasibility; Occurrence of dose-limiting toxicities related to CD33KO-HSPC; Occurrence of dose-limiting toxicities related to CART-33
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.